Portfolio Construction: This portfolio gives exposure to companies that are developing and producing weight-loss drugs such Ozempic and Zepbound. These drugs not only promote a sustainable reduction in body weight, but they also significantly diminish the risks associated with obesity-related health concerns, including heart disease and diabetes.

The stocks in this portfolio are selected by the investment advisor for being highly exposed to modern weight-loss drugs. Updates and rebalances are made at dub Advisors' discretion but are intended to be infrequent.

Risks: This is a portfolio of stocks, and as such may be exposed to the sharp or prolonged declines in value that occur in the stock market. Additionally, this portfolio is highly concentrated in the biotech and pharmaceutical industries, and as such is exposed to higher risks of volatility or larger drawdowns than a diversified stock portfolio. This portfolio is concentrated in a small number of stocks, and is therefore highly exposed to company-specific risks. This portfolio is also exposed to risks specific to weight-loss drugs, including but not limited to the risk that they may turn out to have dangerous side effects, that they may face regulatory obstacles, or that they may turn out to be less popular or profitable than expected for other reasons.